Breaking News

Concert Achieves Avanir Milestone

August 28, 2014

Initiates Phase II trial of AVP-786 in major depressive disorder

Concert Pharmaceuticals has achieved a $2 million milestone under its development and license agreement with Avanir Pharmaceuticals for the clinical progression of AVP-786. Avanir initiated dosing in a Phase II trial for the adjunctive treatment of major depressive disorder.
 
Avanir has worldwide rights to develop and commercialize AVP-786 and other deuterium-modified dextromethorphan (d-DM) compounds, which also have potential to treat neurological and psychiatric disorders.
 
Concert is eligible to receive additional milestones based on certain clinical, regulatory and commercial targets. Avanir will continue to have overall responsibility for R&D and commercialization of d-DM compounds, including AVP-786, and Concert is eligible to receive royalties on sales.
 
“We are very pleased by Avanir’s progress with AVP-786’s clinical development, resulting in a second development milestone to Concert from this program,” said Roger Tung, Ph.D., president and chief executive officer of Concert Pharmaceuticals.

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent